Figure 2

Mean (±SEM) number of premature responses following intra-NAcbS (a) or intra-NAcbC (b) infusions of ATO and following intra-NAcbS (c) or intra-NAcbC (d) infusions of MPH in rats during performance in the 5-CSRTT. Intra-NAcbS treatment with the selective NET inhibitor ATO significantly decreased premature responding at all doses tested (a) whereas infusions of the mixed DAT/NET inhibitor MPH into the NAcbC produced the opposite effect (d). *p<0.05 and **p<0.01, compared with vehicle-treated animals; ##p<0.01, compared with baseline responding (ITI=5.0 s).